

ANNUAL REPORT 2016-2017



**OVARIAN
CANCER
RESEARCH
FOUNDATION**

TABLE OF CONTENTS

FOREWORD FROM CHAIR	3
FOREWORD FROM CEO	3
OUR VISION	4
OUR MISSION	4
OUR OBJECTIVES	4
WHO WE ARE	6
OUR STRATEGIC PLAN	7
OUR RESEARCH	7
A SNAPSHOT OF RECENT SUCCESSES	8
OUR OTHER ACHIEVEMENTS	8
2017-18 SUCCESSFUL GRANT RECIPIENTS	9
OUR COMMUNITY SUPPORTERS	10
OUR MAJOR SUPPORTERS.....	11
OUR MAJOR ACTIVITIES	12-13
AWARENESS & ENGAGEMENT HIGHLIGHTS	13
OUR COMMITTEE OF MANAGEMENT	14
OUR EMPLOYEES	15
OUR PERFORMANCE TO DATE	16
FINANCIAL STATEMENTS	17-18



FOREWORD FROM CHAIR

As new Chair of the Ovarian Cancer Research Foundation (OCRF), I am proud to present the 2016-17 Annual Report which highlights another successful year that takes us one step closer to fulfilling our vision: Every woman, everywhere – free from the threat of ovarian cancer. This year has seen significant change within our Committee and the OCRF office. In late 2016, our two co-founders stood down from their formal positions: our Chair, Associate Professor Tom Jobling and our CEO, Liz Heliotis. Tom and Liz not only initiated the formation of our organisation, but both

tirelessly led and managed the organisation to the success it is today. We are proud of their legacy and of their passion, commitment and dedication to fighting this insidious disease. Tom has generously remained as an Ambassador and continues to advocate for us, while Liz is seeking other opportunities further afield. We wish them every success and thank them again for their achievements and support.

This year has also seen a significant change in the staffing of the OCRF office – and we warmly welcome our new CEO, Lucinda Nolan, our marketing director, Arbel Givargis, our corporate governance coordinator, Erin Eades and our office manager and book-keeper, Lisa Panetta. While they bring a new perspective and way of operating, their passion, commitment and dedication to the cause remains a constant.

The OCRF is firmly focused on the future as we continue to tackle a complex and threatening problem. You will see from the achievements to date, we have had a great year and continue to make significant progress. There is no easy fix or quick solution – but our unwavering focus will take us confidently into the future.



FOREWORD FROM CEO

The Ovarian Cancer Research Foundation has had an exciting year, with some major changes, achievements and new partnerships – all designed to ensure that we continue to be a vibrant, sustainable and relevant organisation. There were many staff changes over the last twelve months, leading to a new and highly committed OCRF team.

Across Australia, one woman dies every 10 hours from ovarian cancer, so it is no surprise that every member of the OCRF team has in some way been touched by the impact of this insidious disease. Our purpose is primarily future-focused: to strive towards a solution, rather than treat the symptoms. We all believe that the key to dealing with this disease is early detection – and you don't need to be a scientist to change the statistics.

We have had many highlights this year, including:

- **Redefining our purpose.** As part of our strategic planning process, we have sharpened our purpose and have now re-defined the OCRF's vision, mission and supporting objectives (see on page 4).
- **Planning for the future.** We have developed a strategic planning framework and are ahead of schedule in implementing the key activities and strategies for the first year.
- **Measuring and enhancing our performance.** We have developed and implemented a raft of performance metrics to ensure we deliver our promises and stay on track.

- **Improving our governance.** We have strengthened our governance framework, systems and processes and brought in additional expertise to assist us in key areas such as scientific advice and marketing functions.
- **Expanding our supporter base and revenue streams.** We have focused on successfully expanding our range of corporate supporters, Ambassadors, community support groups and donors to ensure that we have the level of funds needed to support as many relevant research projects as possible.
- **Working with Government.** We are commencing discussions with all levels of Government around the importance of ovarian cancer research and how we can best work with them.
- **Collaborating with our peers.** We have started working with our cancer research peers to leverage our strengths and collaborate for greater success.
- **Cutting overheads and reducing administrative costs.** We have achieved significant reductions in key line items within our administrative and marketing costs and will continue to focus on reducing costs where we can. The full effect will be evident next financial year.
- **Attracting and funding exciting and innovative ovarian cancer research.** Lastly, but most importantly, we continue to ensure that we encourage and facilitate ease of grant allocations to our best and brightest – in this way, we will increase our chances of success. This year we received the most grant applications in our history and we were able to fund eight individual research proposals as well as continue to fund our ovarian cancer tissue banks. The proposals are cutting-edge and take us one step closer to creating a future where women live free from the threat of ovarian cancer.

We look forward to the next twelve months as we go from strength to strength, and we thank again our generous supporters - for their continued commitment, dedication and assistance. It is much and always appreciated.

OUR VISION

EVERY WOMAN, EVERYWHERE — FREE FROM THE THREAT OF OVARIAN CANCER.

Our latest understanding of ovarian cancer as being a heterogeneous group of different diseases which in many cases originate from the fallopian tube, together with significant advances in laboratory technology, suggests that we have entered a new era of ovarian cancer research. Innovative research will provide the breakthrough needed to eradicate this terrible disease through early detection and better personalised treatment.

OUR MISSION

FUNDING INNOVATIVE OVARIAN CANCER RESEARCH TO SAVE WOMEN'S LIVES THROUGH EARLY DETECTION AND PERSONALISED TREATMENT.

Our funding is directed to research studies that are focused on finding an early detection test, as well as research that explores individualised and targeted therapeutics that will extend women's lives.

OUR OBJECTIVES

THE OCRF HAS THREE MAIN OBJECTIVES:

1. Develop and implement an early detection program for ovarian cancer that is non-invasive, highly accurate and widely available.
2. Improve the mortality rate, management and long-term survival of women with ovarian cancer.
3. Attract and fund the most innovative and skilled researchers.

We rely solely on the financial support of corporate Australia and the community. Once the costs of maintaining our small office are absorbed, all remaining funds are distributed as scientific grants to dedicated ovarian cancer researchers in Australian and New Zealand hospitals, universities and research institutes.

Due to the clarity of our mission and our core proposition – that research is the solution – the OCRF is in a strong, sustainable financial position and is one of the major funding bodies for ovarian cancer research in Australia.

Over 1500 women in Australia are diagnosed every year



**ONLY
20%-25%
OF WOMEN**
diagnosed in advanced
stages of ovarian cancer
will survive beyond 5 years



One woman dies
every 10 hours
from Ovarian
Cancer

AN EARLY DETECTION TEST

could increase
the rate of
survival to over
90%
beyond 5 years





WHO WE ARE

The Ovarian Cancer Research Foundation was established in early 2000 and supports ovarian cancer research in Australia and New Zealand by funding grants to the most innovative and/or promising research proposals that accord with our mission. These grants stimulate and support our researchers in striving to achieve relevant outcomes and to enable effective treatments and cures.

While our major goal is to raise vital research funds for the development of an early detection test to save women's lives, we also provide funding to improve the long-term survival rates of ovarian cancer sufferers. An expectation of the grant allocation is that any discoveries will move towards commercialisation – particularly around the discovery and commercial development of an early detection test – this test needs to be inexpensive, non-invasive and widely available to women around the world.

While the OCRF has significant community reach and remains a major funding body for ovarian cancer research, we are staffed by a very small team of four. By having a small and cross-skilled team, we continue to ensure that the majority of funds we raise flow directly through to our researchers and research institutions.

For several years, the OCRF has also funded the establishment, maintenance and growth of a tissue banking program providing high-quality ovarian cancer specimens for research. The purpose of our tissue banking program is

to manage ovarian cancer tissue collections in support of our related research activities, and additionally support the establishment and evaluation of new clinical trials arising from research findings. Research into ovarian cancer early detection is hampered worldwide by the lack of samples from patients with early stage disease, as only about 10% of cancers are detected early. Consequently, most research groups are working with samples from patients with advanced disease. The issue with this is that identified tumour markers in the advanced stage samples commonly do not reflect early disease and cannot be validated with a large cohort of early stage cases.

Given each year we receive more grant applications than we can potentially fund, we provide access to our tissue banks to any relevant researcher – at no charge – whether or not they are funded by the OCRF.

GRANTS STIMULATE AND SUPPORT OUR RESEARCHERS IN STRIVING TO ACHIEVE RELEVANT OUTCOMES AND TO ENABLE INNOVATIVE TREATMENTS AND CURES.



OUR STRATEGIC PLAN

The Ovarian Cancer Research Foundation's strategic vision for the next three years (2017-2020) is to foster and enhance our reputation as the leading national independent body solely dedicated to funding ovarian cancer research. A strengthened reputation will enable us to build trust and confidence, maintain legitimacy, attract investment, attract and retain quality staff, and build reputation credit for the future.

Key to our success is our ability to build strong and sustainable relationships with our key stakeholders – our community, researchers and research institutions, peers, our corporate and major partners, and Government. This involves listening and learning – and ensuring that our activities are based on evidence and understanding.

We will focus on and enhance the following priority areas:

- LEADERSHIP
- GOVERNANCE
- COST MANAGEMENT
- SERVICES
- WORKPLACE
- INNOVATION
- CITIZENSHIP

OUR RESEARCH

Most of the research previously funded by the Ovarian Cancer Research Foundation can be categorised under the following key general themes:

EARLY DETECTION:

Identifying early events in tumour formation and progression, to help diagnose the presence of ovarian cancer.

Identifying biomarkers that are at a concentration detectable at the early stages of the disease.

PREVENTING METASTASIS:

Investigating methods that may block the ability of the cancer to spread.

PREVENTING CHEMOTHERAPY RESISTANCE:

Looking at the best way to beat chemotherapy resistance, which normally precedes lethal progression of the disease.

PROVIDING PERSONALISED TREATMENT PROGRAMS:

Developing new, targeted, innovative and personalised therapeutics given that ovarian cancer is a heterogeneous group of different diseases.

Sustained OCRF funding has allowed researchers to develop a comprehensive, internationally competitive program of ovarian cancer research. Some of the key outcomes include:

- Development of a novel diagnostic assay for high grade ovarian cancers, aimed at early tumour detection. Based on proven cancer biology, this assay is currently in pre-clinical testing.
- Repurposing of a new anti-diabetes drug for immune stimulation in ovarian cancers, with the potential for rapid clinical translation. This drug is currently being examined in combination with chemo- and immunotherapeutics to provide enhanced anti-cancer efficacy.
- Development of a novel immune targeting strategy designed to halt tumour progression, with the added potential for therapeutic or preventative vaccination.
- Identification of several novel cancer biomarkers, specifically associated with early disease onset, for added efficacy in diagnostic or prognostic profiling.
- Ongoing maintenance of the OCRF sponsored tissue banking program, which has grown to become one of the largest repositories of ovarian cancer tissues for research; over 2200 patients have participated in this program to date.

A SNAPSHOT OF RECENT SUCCESSES

BIOMARKER IDENTIFICATION

The University of Adelaide research team, under the direction of Professor Martin K Oehler, has identified three autoantibodies with high accuracy in detecting early stage ovarian cancer. Their utility for early detection has been validated in an international patient cohort from medical centres in the USA, Canada, Germany, Australia and Singapore. A screening assay for clinical application is currently being developed, and this innovative approach could represent a breakthrough in early ovarian cancer detection.

INNOVATIVE THERAPEUTICS

Other OCRF-funded research projects in Adelaide have investigated the interactions between ovarian cancer cells and the inner lining of the abdominal cavity during the metastatic process. A specific protein was identified which is instrumental for this process. It was also identified in the blood stream of patients and therefore holds considerable promise as both a therapeutic target and diagnostic marker.

CHEMOTHERAPY RESISTANCE

Research by Dr Caroline Ford of the Metastasis Research Group at the Lowy Cancer Research Centre at University of New South Wales studies key pathways responsible for cancer initiation and progression. Two cell receptors have been found to be up-regulated in ovarian cancer cells and to promote metastasis as well as resistance to chemotherapy. Therefore, these cell receptors are potential novel drug targets in metastatic and ovarian cancer patients with recurrent chemo-resistant disease.

OUR OTHER ACHIEVEMENTS

OCRF funding has also built technologically advanced, cutting edge laboratory environments for ovarian cancer research; and permitted the stable retention of scientific expertise, a crucial component for long-term research endeavours. The visionary nature of OCRF funding in this regard has been a crucial feature in driving ongoing success.

In addition to direct research outcomes, the OCRF funding model has been instrumental in raising the profile of ovarian cancer research both nationally and internationally. Our use of experts in the field to filter and select research studies in a strategic manner has led to significant achievements.

Some key achievements include:

- **Global recognition** – OCRF-funded research has been presented at numerous scientific conferences and appeared in national and international media, making a significant contribution to Australia's research profile on the international stage
- **Leveraged funding** – Over \$3 million in independently sourced external funding (both national and international) has been leveraged against OCRF-funded projects, in support of ongoing ovarian cancer research
- **Publications** – arising from OCRF-funded research, hundreds of peer-reviewed scientific articles have been published since 2006
- **Impact on clinical practice** – OCRF-funded projects have contributed to the successful patenting and implementation of specific tests for ovarian cancer, most notably those around a molecule "inhibin" used for the diagnosis and monitoring of specific ovarian tumour types
- **Collaborative research opportunities** – OCRF-funded projects have contributed to multiple inter-institutional and cross-disciplinary research collaborations, involving some of Australia's leading researchers



2017-2018 SUCCESSFUL GRANT RECIPIENTS

The 2017-18 research grants were awarded in June 2017. There was an unprecedented response to the call for grant applications, with the most applications received in the OCRF's 17 year history. A total of \$1.4 million has been awarded, which entails eight research grants and continued tissue bank funding.

The projects were selected in line with the OCRF's key research areas:

1. Identifying biomarkers at the early stages of the disease (5 grants)
2. Investigating methods which block the cancer's ability to spread (1 grant)
3. Developing new, targeted and innovative therapies (2 grants)

CONGRATULATIONS TO ALL RECIPIENTS (SHOWN IN THE TABLE BELOW).

No.	Recipient	Name of Study	Research Institution
1	Dr Andrew N Stephens	Measuring the "CXCL10 Active Ratio" as a Novel Diagnostic Approach to Ovarian Cancer Detection	Hudson Institute of Medical Research
2	Dr Carlos Salomon	Tumour-derived Exosomes as a Signature of Ovarian Cancer – Liquid Biopsies as Indicators of Tumour Progression	Centre for Clinical Diagnostics, UQ
3	Dr Caroline Ford	Not a Whisper, but a ROR! Targeting Novel Receptors in Ovarian Cancer	Lowy Cancer Research Centre, UNSW
4	Dr Kristina Warton	Methylated Circulating DNA in Blood for the Early Diagnosis of Ovarian Cancer	School of Women's and Children's Health, UNSW
5	Professor Martin K Oehler	Autoantibody Biomarkers for Ovarian Cancer Detection	University of Adelaide
6	Professor Martin K Oehler	Ovarian Blood Markers of Ovarian Cancer	University of South Australia
7	Dr Sherry Wu	Re-activating Anti-tumour Immunity by Targeting N-MYC-Let7 Axis in Ovarian Cancer	Lowy Cancer Research Centre, UNSW
8	Dr Simon Chu	1. Efficacy of Smac Mimetics to treat Epithelial Ovarian Cancer and Granulosa Cell Tumours 2. The role of the FOXL2 C134W mutation in Granulosa Cell Tumours	Hudson Institute of Medical Research
9	Professor Martin K Oehler	Biospecimen Collection & Maintenance of Databases (supporting OCRF Tissue Bank)	University of Adelaide
10	Dr Andrew N Stephens	OCRF Tissue Bank at the Hudson Institute	Hudson Institute of Medical Research

OUR COMMUNITY SUPPORTERS

The Ovarian Cancer Research Foundation relies heavily on the generous commitment of our myriad supporters – who work tirelessly in donating, raising funds, or providing in-kind or pro-bono support to ensure that we meet our commitments. Due to this generosity, we have diverse and sustainable revenue streams that are derived from campaigns and events, corporate sponsorships, endowments, foundation and grant income, community fundraising, and general donations and bequests. Ensuring reliable revenues enables us to commit between one and two million dollars in grant allocations each year to the most innovative and promising research proposals received.

SPOTLIGHT ON A SURVIVOR



ONE WOMAN'S STORY – LETITIA LINKE

While ovarian cancer most commonly occurs in women over 50, Letitia Linke's story is a little different.

After embarking on a 2014 health kick and losing 30 kilograms, Letitia was feeling healthier than ever—until she felt a lump in her abdomen.

It took two GPs, a reconstructive surgeon, an MRI, a gynaecologist and an operation to discover the cancerous tumours in Letitia's ovaries. Going into the initial operation, Letitia and her medical team believed the diagnosis to be a bad case of endometriosis.

Had there been an early detection test, Letitia would have been treated months sooner. Early detection would have reduced the significant emotional drain that came with knowing something was wrong but not knowing what it was.

Following surgery, at only 34 years of age, Letitia underwent a radical hysterectomy. She says at that moment, she was so grateful that she had given birth to her two beautiful boys, Ollie and Tommy, during her twenties.

Letitia has endured multiple surgeries, relapse, radiotherapy, and continues with monthly chemotherapy.

While her health issues may have slowed, Letitia's spirit has not. She is a vocal community ambassador for the OCRF, continuing to reach out to the many customers and followers of her design and homewares business, The White Shed, to host fundraising initiatives and educate women about ovarian cancer.

COMMUNITY HEROES



COMMUNITY INSPIRATION – MANDS' MOB

Sisters Georgie and Penny Herbert were always taught to dream big. It was a mindset inspired by their mother Mandy, or Mands to those who knew her.

Mandy was first diagnosed with ovarian cancer in 2005 when little was known about the disease. She referred to it as her 'beastie', and survived through ten rounds of recurrence, before sadly passing away in January 2017 at age 60.

In honour of their mother, Georgie and Penny established Mands' Mob, with the dual aims of raising both public awareness and much needed funds for ovarian cancer research.

The group participates in the annual Run Melbourne half marathon, rallying their supporters to sponsor them or donate directly. They also host a fabulous annual dinner for their network of supporters. Over the past five years, Mands' Mob has raised more than \$300,000 for the OCRF.

This contribution on such a public level helps to spread the word, particularly in striving to educate women about the vague and often misdiagnosed warning signs of ovarian cancer.

The two sisters balance their annual fundraising efforts with high achieving professional careers, and their story demonstrates how local activities with family, friends and colleagues can make a huge difference.

OUR MAJOR SUPPORTERS

The OCRF is thankful for the generous and ongoing support of our Corporate Partners and major donors. The support from our Corporate Partners provides not only vital funds, but also contributes substantially to our awareness raising activities.

WITCHERY

Thank you to the OCRF's Premier Partner Witchery for their ongoing support via the annual White Shirt Campaign. Witchery's commitment to the OCRF has led to significant growth and enabled funding for over 50 research projects since their involvement with the Foundation commenced in 2001.

WITCHERY

MAJOR CORPORATE PARTNERS

Thank you also to Georg Jensen, Simson Cards, oOh Media and Gourmet Traveller for their continued support throughout the 2016-17 financial year.



MAJOR DONORS

Thank you to our major donors, who have provided significant funds to support our research endeavours:

Zimmerman Family Foundation
Bourne Foundation
William Angliss Foundation
JB Were Charitable Endowment Fund

The Wales Family Foundation
Quinn Femelle Private Ancillary Fund
Lord Mayor's Charitable Foundation
A.I. Topper & Co

Brian & Anita Kelly
Sylvia Mary Pavlovic

PRO BONO AND IN-KIND SUPPORTERS

The OCRF would also like to thank the following organisations for their support, energy and contribution throughout the past 12 months:

KPMG
Allens Linklaters
Tech Head
Quantum Market Research

Global Leadership Foundation
NAB
Hatching Communications
Shotover Productions

Sam Miranda
Trumer Pils
San Pellegrino



OUR MAJOR ACTIVITIES

WHITE SHIRT CAMPAIGN



Thanks to Witchery, the 2017 White Shirt Campaign has been another success with the final tally to be revealed at the 2017 Silver Style Event in November. The campaign ran through April and early May, culminating on White Shirt Day, which was celebrated this year on 8 May 2017, World Ovarian Cancer Day. The campaign raises funds primarily from the sale of a specially designed White Shirt range. Witchery generously donates 100% of the proceeds, excluding the GST component, directly to OCRF. The campaign also encourages members of the community to wear their White Shirts and hold fundraising events on White Shirt Day.

The campaign also contributes significant brand awareness for the OCRF, via a substantial outdoor advertising campaign, facilitated by media partner oOh Media, as well as website, social media and PR activities.

FROCKTOBER



The Frocktober campaign was again successfully run in October 2016. This peer-to-peer fundraising campaign requires participants to 'don their dresses' throughout Frocktober, setting themselves challenges and encouraging their family and friends to sponsor their endeavours. The campaign raised over \$310,000 in 2016.

SILVER STYLE


The Silver Style Cocktail Party is the OCRF's annual supporter networking and fundraising event. The 2016 event, held at Melbourne's QT Rooftop Bar, was a highly successful evening with ambassadors, sponsors and other community supporters able to come together, share stories and learn more about how the research is progressing. The evening also raised \$38,000 in revenue via a live auction.

AWARENESS & ENGAGEMENT HIGHLIGHTS

WHITE SHIRT CAMPAIGN 2017

9,645
WHITE SHIRTS SOLD

11,572
SHIRTS & ACCESSORIES



OVER 6.1 MILLION PEOPLE

MEDIA REACH



OVER 2.3 MILLION PEOPLE


OUTDOOR
ADVERTISING
REACH




OVER 750,000 PEOPLE

SOCIAL MEDIA
REACH

OCRF SUPPORTERS



20,000 FOLLOWERS
ON SOCIAL MEDIA



15,000
NEWS
SUBSCRIBERS


OVARIAN
CANCER
RESEARCH
FOUNDATION

OUR COMMITTEE OF MANAGEMENT

The Ovarian Cancer Research Foundation is incorporated under the Victorian Associations Incorporation Reform Act 2012 (AIR Act) and operates under the Rules of the Association adopted by the members on 16 December 2013. The OCRF is also registered as a charity under the Australian Charities and Not-for-profits Commission Act 2012 (ACNC Act). Ultimate responsibility for the governance of the organisation rests with the Committee of Management (the Committee). This statement outlines how the Committee meets that responsibility.

COMMITTEE OF MANAGEMENT'S ROLE AND MEMBERSHIP

The Committee's primary role is to ensure that the OCRF's activities are directed towards achieving our mission of developing an early detection test for ovarian cancer; improving the mortality rate, management and long-term survival of women with ovarian cancer; as well as attracting and funding the most innovative and skilled researchers.

Fulfilling this primary role involves core duties of:

- determining, reviewing and maintaining the vision, purpose and values of the organisation;
- approving short and long-term strategies and policies;
- approving annual budgets;
- overseeing and mitigating risk;
- providing a check on the integrity of external financial and non-financial reports;
- supporting effective engagement with key stakeholders, partners, donors and the community; and
- performance evaluation of management.

These responsibilities are detailed in the Committee of Management's Charter, the OCRF's Rules and Governance Framework.

ADVISORY SUBCOMMITTEES

The Committee has established subcommittees it considers appropriate. The Committee charges subcommittees with the responsibility to consider detailed issues and make appropriate recommendations to the Committee. Each subcommittee operates under a Terms of Reference approved by the Committee. These Terms of Reference are reviewed annually and updated as necessary. Every Committee Member is a member of at least one of our advisory subcommittees and subcommittees also comprise several independent members. Currently the Committee has established two advisory subcommittees:

SCIENTIFIC ADVISORY COMMITTEE (SAC)

This subcommittee supports the Committee in discharging its responsibilities by providing expert advice, recommendations and assurance in the awarding of research funding according to the OCRF's mission. SAC meets at least twice annually.

MARKETING & FUNDRAISING ADVISORY COMMITTEE (MFAC)

This newly-established subcommittee supports the Committee in discharging its responsibilities by providing guidance and assurance regarding marketing, fundraising and partnership strategic direction, planning and development. MFAC meets at least four times annually.

COMMITTEE OF MANAGEMENT MEMBERS

Ms Julie Toop, Chair
Mr Paul Ashworth, Vice-Chair
Ms Emma Clark, Treasurer
Dr Geraldine Goss, Secretary
Dr L. Jane McNeilage, Ordinary Member
Professor Martin K Oehler, Ordinary Member
Mr Anthony Pyman, Ordinary Member

Past Members

Associate Professor Thomas Jobling, Previous Chair & Co-Founder
Ms Liz Heliotis, Previous CEO & Co-Founder

OUR EMPLOYEES



LUCINDA NOLAN - CEO

Lucinda Nolan is the CEO of the Ovarian Cancer Research Foundation and has a wealth of knowledge and experience across the public sector and as a director for several boards. Prior to joining the OCRF, she was selected as the first female CEO of the Country Fire Authority, one of the world's largest volunteer based emergency services organisation. She also spent 32 years with Victoria Police, reaching the rank of Deputy Commissioner and was awarded the Australian Police Medal in 2009. Lucinda is a director on the Boards of Hawthorn Football Club, BankVic, Youth Support and Advocacy Services (YSAS) and the Penington Institute. She has a Master of Arts and a Bachelor of Arts (Honours) from Melbourne University and completed the Advanced Management Program at Harvard University.

Lucinda's sister-in-law, Jane, died of ovarian cancer at the young age of 54. On diagnosis, her prognosis was poor as the cancer was detected in the advanced stages of the disease. This tragic event has reaffirmed to Lucinda that to save women's lives, we need to find and develop a test for early detection. Research is the answer.



LISA PANETTA – OFFICE MANAGER

Lisa is a chartered accountant and has a range of experience working with not-for-profit organisations, including as project manager at the Australian Accounting Standards Board (AASB) and as assistant manager at Moore Stephens, an accounting firm. With her previous experience, Lisa brings a wealth of knowledge in ensuring the financial management and practices of the OCRF are clear and transparent.

In her role at the OCRF, Lisa speaks to many patients, survivors and those who have lost loved ones to ovarian cancer. Lisa is moved by their courage, strength and determination to fight this terrible disease. Lisa makes it her mission to provide as much support and guidance as possible. Lisa's awareness of ovarian cancer as an insidious disease that does not discriminate, came when a close family member lost her 5-year battle with the disease at the young age of 23.



ERIN EADES – CORPORATE GOVERNANCE COORDINATOR

Erin has wide-ranging experience and formal qualifications in corporate governance and has held several key governance positions in very different organisational contexts. Having provided high level support to Boards and Executive teams, she brings a wealth of knowledge in connecting governance processes and improving procedures to the OCRF. With a background in the tertiary sector, Erin is well placed to support the OCRF in its pursuit to invest in the most innovative research in ovarian cancer. Erin has always been community minded, with a keen interest in supporting culturally and linguistically diverse (CALD) communities. She has volunteered for organisations such as Foundation House and completed an Honours thesis in communicating risk to CALD communities. As a bit of an Italophile, Erin returns to Italy frequently to brush up on her language skills.

Ovarian cancer came into sharp focus for Erin with the loss of her Aunty to this insidious disease in 2016. The unexpected nature of Caz's demise highlighted - in a profoundly personal way - that women deserve to live their lives without fear of ovarian cancer.



ARBEL GIVARGIS – MARKETING DIRECTOR

Arbel is an experienced marketer and relationship manager. He holds tertiary qualifications in Marketing and Management and brings a breadth of experience, having worked in both the corporate and not-for-profit sectors. Arbel is passionate about developing deep and ongoing relationships with the OCRF's key stakeholders, as well as building on the Foundation's core campaigns to encourage even more donors to engage with and support the cause. Arbel is also actively involved in the community - where he sits on the board of xpanse Foundation (a social enterprise), is a committee member at East Camberwell Tennis Club, and performs a volunteer role at Murrumbena Primary School.

Arbel became acutely aware of ovarian cancer with the premature passing of a close friend's mother from the disease in 2016. Arbel's wife also lost her grandmother to ovarian cancer and an aunt is currently fighting the disease, making the cause even more personal.

OUR PERFORMANCE TO DATE

LEADERSHIP

We have reviewed and refined our vision, mission, values and direction.

We have developed and implemented an integrated planning process.

We have developed and diversified our communication methods and modes.

GOVERNANCE

We have continued to build a high functioning, strategic and skilled Committee of Management and supporting subcommittees.

We have developed and implemented a risk management framework including tailored policies and processes.

We have refined our governance systems and processes to ensure transparency and accountability.

COST MANAGEMENT

We have implemented a cost reduction strategy.

We measure and track financial metrics to ensure that we consistently reduce overheads, allowing most of our revenue to flow directly into funding research.

The impact of the cost reduction strategy will take effect next financial year.

SERVICES

We have strengthened research excellence by improving our grant and funding processes and success criteria.

We have initiated and developed strong stakeholder relationships.

We have increased and diversified our revenue streams.

We have developed and published an annual report outlining research progress and success to date.

WORKPLACE

We have continually worked towards a high performing, skilled and cohesive OCRF team.

We have set clear expectations around customer and stakeholder centric service within a collegiate and respectful workplace.

INNOVATION

We have built and demanded a culture of innovation and continuous improvement – both within the organisation and from our successful grant recipients.

CITIZENSHIP

We continuously work towards enhancing our reputation and national presence by understanding our stakeholders' views and perceptions of us, linking with the broader cancer research community, communicating our successes and strengthening our brand.

**RAISING AWARENESS AROUND
OVARIAN CANCER AND ITS SYMPTOMS
WON'T SAVE LIVES.**

**VIABLE RESEARCH IS THE ANSWER
AND EARLY DETECTION IS THE KEY.**



**OVARIAN
CANCER
RESEARCH
FOUNDATION**

FINANCIAL STATEMENTS

The Ovarian Cancer Research Foundation has worked towards increasing and diversifying our income streams to enable us to continue to be a vibrant, sustainable and relevant organisation. The following information is based on the audited financial statements of the OCRF.

STATEMENT OF COMPREHENSIVE INCOME

For the year ended 30 June 2017.

INCOME	2016-17	2015-16
Corporate Sponsorship	1,788,758	2,072,632
Individual & Community Donations	919,409	1,052,333
Philanthropic Giving	242,800	134,436
Other Income	130,969	123,189
Total Income for the year	3,081,936	3,382,590
EXPENDITURE		
Administration	834,497	800,920
Advertising & Fundraising Campaigns	360,572	358,154
Total Expenditure	1,195,069	1,159,074
Surplus from ordinary activities before grant payments	1,886,867	2,223,516
GRANT PAYMENTS		
Grants paid during the year	1,557,747	1,431,178
Total Grants Payments	1,557,747	1,431,178
Total Comprehensive Income	329,120	792,338

STATEMENT OF FINANCIAL POSITION

For the year ended 30 June 2017


ASSETS	2016-17	2015-16
Current Assets	5,095,740	4,953,372
Non-Current Assets	23,536	24,689
Total Assets	5,119,276	4,978,061
LIABILITIES		
Current Liabilities	110,815	297,222
Non-Current Liabilities	231	1,729
Total Liabilities	111,046	298,951
Net Assets	5,008,230	4,679,110

STATEMENT OF CASH FLOWS


For the year ended 30 June 2017

CASH FLOW FROM OPERATING ACTIVITIES	2016-17	2015-16
Sponsorship Revenue	1,775,520	2,001,303
Donations and Functions Receipts	1,158,879	1,262,229
Interest received	130,748	118,879
Payments to Suppliers and Employees	(1,367,397)	(1,285,232)
Grants Paid	(1,557,747)	(1,431,178)
Total Cash Flow From Operating Activities	140,003	666,001
CASH FLOW FROM INVESTING ACTIVITIES		
Transfer of cash from/(to) term deposit	(297,299)	(687,068)
Purchase of plant and equipment	(5,165)	(698)
Proceeds from sale of plant and equipment	350	5,661
Total Cash Flow From Investing Activities	(302,114)	(682,105)
Net (Decrease)/Increase in Cash	(162,111)	(16,104)
Cash Balance at the Beginning of the Year	891,314	907,418
Cash Balance at the End of the Year	729,203	891,314

RESEARCH GRANTS AWARDED 2014-16



INCOME 2017



HOW TO SUPPORT US

CONTACT US

The Ovarian Cancer Research Foundation Inc.
TOK Corporate Centre
Level 1, 459 Toorak Road
Toorak VIC 3142

1300 OVARIAN (1300 682 742)

community@ocrf.com.au

ABN: 24 898 129 866

ABRN: 130 949 834

 <https://ocrf.com.au/>

 Facebook: @OCRFaustralia

 Instagram: @ocrf

 Twitter: @ocrfaustralia



**VISIT [OCRF.COM.AU](https://ocrf.com.au)
TO DONATE NOW**